ArticleJournal of translational medicine2026
DHX37 and tumor growth: a novel avenue for melanoma research.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionThis study explores a novel mechanism by which the RNA helicase DHX37 contributes to melanoma and elucidates the reasons for resistance to tumor immunotherapy, providing new insights for the treatment of melanoma.
methodThis study integrated multiomics data for systematic analysis. The prognostic value of the candidate differentially expressed genes was assessed on the basis of public databases. Single-cell transcriptome data were used to determine the expression patterns of key genes and elucidate intercellular communication networks. Finally, in vitro and in vivo experiments confirmed the mechanism of action of DHX37 in melanoma.
resultsTen key candidate genes that were differentially expressed between primary and metastatic melanoma were identified. Among them, the RNA helicase DHX37 was significantly overexpressed in metastatic tissues, and its high expression was significantly associated with poor overall survival (OS) and shorter progression-free survival (PFS). Functional enrichment analysis revealed that high DHX37 expression was closely related to DNA repair and immune response pathways. Immunological analysis revealed that high DHX37 expression was associated with the formation of an immunosuppressive microenvironment. Single-cell analysis further revealed that DHX37 was specifically expressed primarily in melanoma cells and endothelial cells. In vitro experiments confirmed that knockdown of the DHX37 gene in melanoma cells significantly inhibited tumor cell proliferation and migration. Coculturing DHX37 knockdown melanoma cells with CD8 + T cells significantly increased the secretion of related cytokines. Animal experiments demonstrated that DHX37 knockdown in melanoma cells resulted in smaller tumors and more related immune cytokines.
conclusionThis study systematically identified the multiple functions of DHX37 in melanoma progression, suggesting that DHX37 can serve as a potential prognostic biomarker and therapeutic target, providing new insights for precision therapy in melanoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.